clinical trial · NCT06840483
Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
BicycleTx Limited·phase2·active not recruiting·n = 66
Breast CancerZelenectide pevedotin (BT8009)
brief summary
This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with NECTIN4-amplified recurrent, unresectable, or metastatic breast cancer who have received prior therapy (see inclusion criteria below). The study will comprise of 2 cohorts. Cohort A will include participants with hormone receptor positive/ human epidermal growth factor receptor 2 negative \[HR+/HER2-\] breast cancer, whereas Cohort B will include participants with triple-negative breast cancer (TNBC).
started
Mar 3, 2025
primary completion
Jun 30, 2028
completion
Dec 30, 2028
last updated
Apr 15, 2026
official title
Phase 2 Study of Zelenectide Pevedotin in Participants With NECTIN4 Amplified Advanced Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol